Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dermatomyositis (DM) AND Dermatomyositis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Dermatomyositis (DM) AND Dermatomyositis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-004787-10 Sponsor Protocol Number: C0251008 Start Date*: 2022-03-07
    Sponsor Name:Pfizer Inc.
    Full Title: AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS.
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) ES (Ongoing) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005772-34 Sponsor Protocol Number: CL2-78989-010 Start Date*: 2013-06-17
    Sponsor Name:Institut de Recherches Internationales Servier (IRIS)
    Full Title: A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis o...
    Medical condition: Polymyositis / Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) SE (Completed) DE (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004410-13 Sponsor Protocol Number: 3401 Start Date*: 2008-03-12
    Sponsor Name:Institute od Rheumatology Prague
    Full Title: A PROSPECTIVE, RANDOMISED, ASSESSOR-BLIND, MULTICENTER STUDY OF EFFICACY AND SAFETY OF COMBINED TREATMENT OF METHOTREXATE + GLUCOCORTICOIDS VERSUS GLUCOCORTICOIDS ALONE IN PATIENTS WITH POLYMYOSITI...
    Medical condition: active polymyositis, dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012503 Dermatomyositis LLT
    9.1 10036102 Polymyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004228-41 Sponsor Protocol Number: C0251002 Start Date*: 2021-07-28
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000898-83 Sponsor Protocol Number: ADN016 Start Date*: 2021-11-10
    Sponsor Name:ADIENNE SA
    Full Title: A phase II, randomized, double-blind, placebo-controlled, two-period, crossover trial to assess the efficacy and safety of begelomab in combination with standard steroid and/or immunosuppressant th...
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002710-31 Sponsor Protocol Number: SCGAM-02 Start Date*: 2018-08-20
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H
    Full Title: DOUBLE-BLIND, RANDOMIZED, PLACEBO- CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH DERMATOMYOSITIS.
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001799-39 Sponsor Protocol Number: CBAF312X2206 Start Date*: 2013-09-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis.
    Medical condition: Active dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006311-21 Sponsor Protocol Number: CBAF312A2202 Start Date*: 2009-07-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis
    Medical condition: Polymyositis and dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036102 Polymyositis LLT
    9.1 10012503 Dermatomyositis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-001200-15 Sponsor Protocol Number: ALXN1210-DM-310 Start Date*: 2021-10-05
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis.
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000506-10 Sponsor Protocol Number: APHP211036 Start Date*: 2022-06-21
    Sponsor Name:Assistance Publique des Hôpitaux de Paris
    Full Title: Bariticinib in the treatment of new-onset juvenile dermatomyositis :a phase II trial
    Medical condition: New-onset juvenile dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10008521 Childhood dermatomyositis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000391-15 Sponsor Protocol Number: AIFA-2016-02364869 Start Date*: 2018-06-05
    Sponsor Name:Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia
    Full Title: Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis
    Medical condition: Myositis (dermatomyositis [DM] or polymyositis [PM])
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028653 Myositis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003277-15 Sponsor Protocol Number: 8400-211 Start Date*: 2016-09-02
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000137-52 Sponsor Protocol Number: IFN-K-005-DM Start Date*: 2016-07-26
    Sponsor Name:Neovacs SA
    Full Title: A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects with Dermatomyositis.
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003273-10 Sponsor Protocol Number: JBT101-DM-002 Start Date*: 2019-05-21
    Sponsor Name:Corbus Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
    Medical condition: Dermatomyositis (DM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) CZ (Completed) BG (Completed) SE (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015957-20 Sponsor Protocol Number: ARTEMIS Start Date*: 2010-02-16
    Sponsor Name:Karolinska University Hospital
    Full Title: Abatacept treatment in polymyositis and dermatomyositis
    Medical condition: polymyositis and dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036102 Polymyositis LLT
    12.1 10012503 Dermatomyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) CZ (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004987-24 Sponsor Protocol Number: APHP180612 Start Date*: 2021-02-18
    Sponsor Name:Assistance Publique-Hopitaux de Paris
    Full Title: Baricitinib in patients with relapsing or naïve dermatomyositis
    Medical condition: Baricitinib in patients with relapsing or naïve dermatomyositis.Multicenter trial, double blind randomized controlled trial with 2 parallel groups. This is an add-on trial with intention to treat a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10001403 Adult dermatomyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003171-35 Sponsor Protocol Number: IgPro20_3007 Start Date*: 2019-09-24
    Sponsor Name:CSL Behring LLC
    Full Title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM)
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10001403 Adult dermatomyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001762-11 Sponsor Protocol Number: JBT101-LTS-001 Start Date*: 2020-08-26
    Sponsor Name:Corbus Pharmaceuticals, Inc.
    Full Title: An Observational Long-Term Safety Surveillance of Participants from Corbus Sponsored Lenabasum Pivotal Clinical Trials
    Medical condition: Dermatomyositis (DM) is a rare and serious autoimmune disease.An overactive immune response causes chronic inflammation,which results in growth of scar tissue in the skin,muscles,and many internal ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SE (Completed) GB (Completed) AT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002902-37 Sponsor Protocol Number: GAM10-08 Start Date*: 2016-12-20
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H.
    Full Title: PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10001403 Adult dermatomyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) NL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-003633-42 Sponsor Protocol Number: RBHIPF004 Start Date*: 2013-10-18
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
    Medical condition: A diagnosis of connective tissue disease associated interstitial lung disease, based on internationally accepted criteria, in one of the following categories: o Systemic sclerosis o Idiopathic inte...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10027754 Mixed connective tissue disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039710 Scleroderma PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:33:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA